For those of you who are following herpes vaccines in development, the news out of Australia isn't bad. Or especially good.

Admedus released results from its Phase IIa (1) clinical trials of it herpes simplex 2 vaccine, and even the company didn't seem all that enthusiastic. That's OK. Unlike some other companies, they are not hyping early results to try and get funding or media coverage. The endpoint of the trial was safety, which was achieved, but not much else. The company said "positive immune response to the vaccine was seen in most [of the 34] subjects." (2)

Also reported:

  • A positive immune response was seen in "most...